Editas Medicine, Inc. (EDIT)Healthcare | Biotechnology | Cambridge, United States | NasdaqGS
3.16 USD
-0.14
(-4.242%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 3.14 -0.02 (-0.019%) ⇩ (Aug. 28, 2026, 7:52 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 5:51 a.m. EDT
The investment case for Editas Medicine is currently broken by a severe structural decline and deteriorating fundamentals. The stock has suffered a catastrophic -85.58% drop over the last nine years, with four consecutive years of negative annual returns, signaling that the market has permanently reassessed the business quality downward. Financials confirm this distress: the company is burning cash with negative free cash flow, negative operating margins, and negative gross margins, while returning capital to shareholders via buybacks despite having no earnings to support such actions. The balance sheet, while currently liquid, is fragile given the ongoing burn rate and lack of profitability. While the analyst consensus remains 'Buy' with a target of $6, this appears to be a lagging indicator of past highs rather than a reflection of current reality, especially given the recent news of executives selling shares and analysts cutting estimates. The options market reflects this pessimism, with heavy positioning in deep out-of-the-money puts acting as insurance against further collapse. There is no catalyst visible to reverse this multi-year downtrend, making this a dangerous environment for both short-term traders and long-term investors. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.093977 |
| AutoETS | 0.100464 |
| AutoARIMA | 0.100465 |
| AutoTheta | 0.131495 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 0.32 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.286 |
| Excess Kurtosis | -0.53 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 14.733 |
| Revenue per Share | 0.464 |
| Market Cap | 485,312,928 |
| Forward P/E | -4.20 |
| Beta | 2.06 |
| Profit Margins | -157.32% |
| Website | https://www.editasmedicine.com |
As of Aug. 22, 2026, 5:51 a.m. EDT: Speculators are heavily positioning for downside protection, evidenced by massive open interest in deep out-of-the-money puts (strikes at 0.5, 1.0, and 1.5) relative to volume, indicating a fear of a collapse to these levels. Conversely, call activity is concentrated in the money (ATM) and slightly out-of-the-money strikes (5.0), suggesting a speculative hope for a rebound to the mean rather than a breakout to higher targets. The disparity in put volume versus call volume at lower strikes highlights a dominant bearish sentiment.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.2793522 |
| Address1 | 11 Hurley Street |
| All Time High | 99.95 |
| All Time Low | 0.91 |
| Ask | 3.18 |
| Ask Size | 1 |
| Audit Risk | 4 |
| Average Analyst Rating | 2.1 - Buy |
| Average Daily Volume10 Day | 3,550,390 |
| Average Daily Volume3 Month | 2,450,834 |
| Average Volume | 2,450,834 |
| Average Volume10Days | 3,550,390 |
| Beta | 2.063 |
| Bid | 3.25 |
| Bid Size | 13 |
| Board Risk | 7 |
| Book Value | 0.686 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.16 |
| Current Ratio | 3.187 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 3.4099 |
| Day Low | 3.15 |
| Debt To Equity | 14.733 |
| Display Name | Editas Medicine |
| Earnings Call Timestamp End | 1,723,032,000 |
| Earnings Call Timestamp Start | 1,723,032,000 |
| Earnings Timestamp | 1,785,960,000 |
| Earnings Timestamp End | 1,794,254,400 |
| Earnings Timestamp Start | 1,794,254,400 |
| Ebitda | -81,035,000 |
| Ebitda Margins | -1.72397 |
| Enterprise To Ebitda | -3.569 |
| Enterprise To Revenue | 6.152 |
| Enterprise Value | 289,178,912 |
| Eps Current Year | -0.82929 |
| Eps Forward | -0.75313 |
| Eps Trailing Twelve Months | -0.63 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.9806 |
| Fifty Day Average Change | 0.17939997 |
| Fifty Day Average Change Percent | 0.06018921 |
| Fifty Two Week Change Percent | 27.935219 |
| Fifty Two Week High | 4.537 |
| Fifty Two Week High Change | -1.3770001 |
| Fifty Two Week High Change Percent | -0.30350453 |
| Fifty Two Week Low | 1.66 |
| Fifty Two Week Low Change | 1.5000001 |
| Fifty Two Week Low Change Percent | 0.9036145 |
| Fifty Two Week Range | 1.66 - 4.537 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,454,509,800,000 |
| Float Shares | 115,495,258 |
| Forward Eps | -0.75313 |
| Forward P E | -4.1958227 |
| Free Cashflow | -44,316,000 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 87 |
| Fullday Change | -0.14 |
| Fullday Change Percent | -4.24242 |
| Fullday Price | 3.1407 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | -0.80745006 |
| Gross Profits | -37,954,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00183 |
| Held Percent Institutions | 0.79209 |
| Implied Shares Outstanding | 153,580,035 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts. |
| Long Name | Editas Medicine, Inc. |
| Market | us_market |
| Market Cap | 485,312,928 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_252050056 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -73,949,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 506,814,115 |
| Number Of Analyst Opinions | 9 |
| Open | 3.25 |
| Operating Cashflow | -119,859,000 |
| Operating Margins | -1.6730901 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 617 401 9000 |
| Post Market Change | -0.019299984 |
| Post Market Change Percent | -0.61075896 |
| Post Market Price | 3.1407 |
| Post Market Time | 1,787,961,160 |
| Previous Close | 3.3 |
| Price Eps Current Year | -3.8104887 |
| Price Hint | 4 |
| Price To Book | 4.6064143 |
| Price To Sales Trailing12 Months | 10.324709 |
| Profit Margins | -1.57322 |
| Quick Ratio | 3.133 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.07692 |
| Region | US |
| Regular Market Change | -0.14 |
| Regular Market Change Percent | -4.24242 |
| Regular Market Day High | 3.4099 |
| Regular Market Day Low | 3.15 |
| Regular Market Day Range | 3.15 - 3.4099 |
| Regular Market Open | 3.25 |
| Regular Market Previous Close | 3.3 |
| Regular Market Price | 3.16 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 3,267,144 |
| Return On Assets | -0.23290001 |
| Return On Equity | -1.18822 |
| Revenue Growth | 2.323 |
| Revenue Per Share | 0.464 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 153,580,035 |
| Shares Percent Shares Out | 0.1607 |
| Shares Short | 24,686,466 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 22,197,638 |
| Short Name | Editas Medicine, Inc. |
| Short Percent Of Float | 0.161 |
| Short Ratio | 16.36 |
| Source Interval | 15 |
| State | MA |
| Symbol | EDIT |
| Target High Price | 15.0 |
| Target Low Price | 1.0 |
| Target Mean Price | 6.0 |
| Target Median Price | 5.0 |
| Total Cash | 211,644,992 |
| Total Cash Per Share | 1.378 |
| Total Debt | 15,511,000 |
| Total Revenue | 47,005,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.63 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.601025 |
| Two Hundred Day Average Change | 0.558975 |
| Two Hundred Day Average Change Percent | 0.21490565 |
| Type Disp | Equity |
| Volume | 3,267,144 |
| Website | https://www.editasmedicine.com |
| Zip | 2,141 |